➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Merck
Colorcon
Mallinckrodt
Dow

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,775,851


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,775,851 protect, and when does it expire?

Patent 9,775,851 protects SERNIVO and is included in one NDA.

This patent has six patent family members in four countries.

Summary for Patent: 9,775,851
Title:Topical formulations comprising a steroid
Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Inventor(s): Ubaidulla; Udhumansha (Namakkal, IN), Kandavilli; Sateesh (Plainsboro, NJ), Vairale; Ajay Sunil (Hyderabad, IN), Wayne; Jeffrey A. (Markham, CA), Nalamothu; Vijendra (Basking Ridge, NJ), Meghal; Mistry (Ahmedabad, IN), Pakunlu; Refika Isil (Highland Park, NJ)
Assignee: Dr. Reddy's Laboratories, Ltd. (Hyderabad, Telangana, IN)
Application Number:15/495,148
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,775,851
Patent Claim Types:
see list of patent claims
Use; Composition; Device;

Drugs Protected by US Patent 9,775,851

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Primus Pharms SERNIVO betamethasone dipropionate SPRAY;TOPICAL 208079-001 Feb 5, 2016 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y TREATMENT OF PLAQUE PSORIASIS ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,775,851

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
India2111/CHE/2009Aug 31, 2009

International Family Members for US Patent 9,775,851

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark 2473161 ⤷  Free Forever Trial
European Patent Office 2473161 ⤷  Free Forever Trial
European Patent Office 3141246 ⤷  Free Forever Trial
Japan 2013503203 ⤷  Free Forever Trial
Japan 5833007 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 2011026076 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Merck
Mallinckrodt
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.